Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31432759 | 1.00 | DPP7 (0.44) | DPP7DPP8DPP9DPP4NAMPT | |
| SCHEMBL31432718 | 1.00 | DPP7 (0.44) | DPP7DPP8DPP9DPP4NAMPT | |
| SCHEMBL31432712 | 0.89 | NAMPT (0.43) | DPP7DPP8DPP9DPP4NAMPT | |
| SCHEMBL31432782 | 0.88 | HSD17B3 (0.50) | DPP7DPP8DPP9DPP4NAMPT | |
| SCHEMBL31432828 | 0.88 | HSD17B3 (0.50) | DPP7DPP8DPP9DPP4NAMPT | |
| SCHEMBL31542160 | 0.87 | ALDH1A1 (0.51) | DPP7DPP8DPP9DPP4PTPN11 | |
| SCHEMBL31432763 | 0.87 | ALDH1A1 (0.51) | DPP7DPP8DPP9DPP4PTPN11 | |
| SCHEMBL31432714 | 0.87 | ALDH1A1 (0.51) | DPP7DPP8DPP9DPP4PTPN11 | |
| SCHEMBL31432805 | 0.80 | LTB4R2 (0.50) | NAMPTPTPN11AGTR1AGTR2 | |
| SCHEMBL31432853 | 0.80 | POLB (0.46) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025088073-A1 | HETEROCYCLIC COMPOUNDS AS BLT2 AGONISTS AND THEIR MEDICAL USE | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2025-05-01 | — | — | WO | disclosed |